SCHEMBL3296751

SCHEMBL3296751

CCCCC1(c2ccncc2)CCC(=O)NC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9531145 0.95 CYP19A1 (1.00) CYP19A1
Rogletimide SCHEMBL9372682 0.85 CYP19A1 (1.00) CYP19A1
Rogletimide SCHEMBL4281 0.85 CYP19A1 (1.00) CYP19A1
Rogletimide SCHEMBL28110686 0.83 CYP19A1 (0.94) CYP19A1
SCHEMBL10514138 0.76 CYP19A1 (0.68) CYP19A1
Safingol SCHEMBL28069970 0.76 CYP19A1 (0.62) CYP19A1
Safingol SCHEMBL28140538 0.75 CYP19A1 (0.61) CYP19A1
SCHEMBL13465305 0.74 CYP19A1 (0.60) CYP19A1
SCHEMBL20805215 0.71 CYP19A1 (0.60) CYP19A1
Phenglutarimide SCHEMBL1649930 0.70 CYP19A1 (0.56) CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080794-A1 Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders VIVUS INC (US) 2014-03-20 US disclosed
US-20100087402-A1 Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders VIVUS, INC. (US) 2010-04-08 US disclosed